Subscribe To

Price Alert Latest News Economic Calendar News

VTGN / What Makes VistaGen Therapeutics, Inc. (VTGN) a New Buy Stock

VistaGen Therapeutics, Inc. (VTGN) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy). Read More

Demo Live Account See Partner Details

Content Topics

vtgn

Posted: Nov 15 2022, 13:33

Author Name: Zacks Investment Research

VTGN News

By Seeking Alpha
August 13, 2023

Vistagen Therapeutics, Inc. (VTGN) Q1 2024 Earnings Call Transcript

Vistagen Therapeutics, Inc. (NASDAQ:VTGN ) Q1 2024 Earnings Conference Call August 10, 2023 4:30 PM ET Company Participants Mark Flather - VP of IR Sh

By Schaeffers Research
August 10, 2023

Outperforming Biotech Pops on Shareholder Buzz

Vistagen Therapeutics Inc (NASDAQ:VTGN) is continuing its recent volatility, after today's news that healthcare investment name Commodore Capital Mast

By InvestorPlace
August 7, 2023

Why Is Vistagen Therapeutics (VTGN) Stock Up 650% Today?

Vistagen Therapeutics (NASDAQ: VTGN ) stock is surging to impressive levels today on news of some positive trial results. The pharmaceutical producer

By PennyStocks
August 7, 2023

VistaGen Therapeutics (VTGN Stock) Exploded 3,471% Here's Why

Are you looking for penny stocks to buy? Are you grappling with the push and pull of skeptics saying penny stocks aren't worth it or penny stocks are

By Business Wire
June 27, 2023

Vistagen to Announce Fiscal Year 2023 Financial Results and Provide Corporate Update Conference Call on June 28, 2023

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)---- $VTGN #mentalhealth--Vistagen (NASDAQ: VTGN), a late clinical-stage biopharmaceutical company aiming

By Seeking Alpha
February 10, 2023

VistaGen Therapeutics, Inc. (VTGN) Q3 2023 Earnings Call Transcript

VistaGen Therapeutics, Inc. (NASDAQ:VTGN ) Q3 2023 Earnings Conference Call February 7, 2023 5:00 PM ET Company Participants Mark Flather - Vice Presi

By Zacks Investment Research
February 7, 2023

VistaGen Therapeutics, Inc. (VTGN) Reports Q3 Loss, Misses Revenue Estimates

VistaGen Therapeutics, Inc. (VTGN) delivered earnings and revenue surprises of 16.67% and 41.94%, respectively, for the quarter ended December 2022. D

By Business Wire
February 6, 2023

Vistagen to Report Fiscal Year 2023 Third Quarter Financial Results on February 7, 2023

SOUTH SAN FRANCISCO, Calif.--( BUSINESS WIRE )--Vistagen (NASDAQ: VTGN), a late clinical-stage biopharmaceutical company aiming to transform the treat

Risk Disclosure:

Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
We would like to remind you that the data contained in this website is not necessarily real-time nor accurate.
The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. We and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of us and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website. We may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.

Subscribe To

Live Trading Account

Open live account in few minutes with just 10$

VTGN / What Makes VistaGen Therapeutics, Inc. (VTGN) a New Buy Stock

What

Makes

Vistagen

Therapeutics

Inc

VTGN

Stock